Financial Performance - Revenues for the three months ended March 31, 2025, were $10,258, compared to $0 in the same period of 2024, indicating a significant increase[17]. - Gross profit for Q1 2025 was $673, resulting in a gross margin of approximately 6.56%[17]. - Operating loss for the first quarter of 2025 was $3.57 million, an improvement from a loss of $5.49 million in Q1 2024[17]. - Net loss from continuing operations for Q1 2025 was $3.06 million, compared to a loss of $6.63 million in the same quarter of the previous year, showing a reduction of approximately 53.91%[17]. - For the three months ended March 31, 2025, the net loss from continuing operations was $3,063,997, a decrease of 54% compared to a net loss of $6,633,422 for the same period in 2024[1]. - The company incurred a net loss from operations of $3,063,997, a 54% improvement compared to a net loss of $6,633,422 in the same period in 2024[194]. - Net (loss) income for the three months ended March 31, 2025, was $(3,063,997), a decrease of 114% compared to net income of $21,246,033 in the same period in 2024[185]. Assets and Liabilities - Total assets increased to $106.36 million as of March 31, 2025, compared to $104.85 million at the end of 2024, reflecting a growth of approximately 1.44%[13]. - Total current liabilities decreased to $7.46 million as of March 31, 2025, from $7.91 million at the end of 2024, a decline of about 5.67%[13]. - Cash balance increased significantly to $2.05 million as of March 31, 2025, compared to $308,096 at the end of 2024, representing a growth of over 564%[13]. - The company reported an accumulated deficit of $42.10 million as of March 31, 2025, compared to $39.04 million at the end of 2024[15]. - Total stockholders' equity increased to $81.16 million as of March 31, 2025, from $79.07 million at the end of 2024, reflecting a growth of approximately 2.66%[15]. Cash Flow - Net cash used in operating activities from continuing operations was $2,956,457, significantly reduced from $9,659,231 in the prior year[1]. - The company reported a net cash provided by investing activities of $27,432,589, primarily due to proceeds from discontinued operations[1]. - Cash used in operating activities for the three months ended March 31, 2025, was $2,956,457, a decrease of 71% compared to $10,189,673 for the same period in 2024[181]. Strategic Transactions - The company plans to divest its membership interests in Integra Pharma Solutions, LLC and Bonum Health, Inc. to Tollo Health, Inc. for a total consideration of $5 million[28][31]. - The divestitures are part of a strategic realignment aimed at optimizing the company's portfolio and accelerating growth in the Branded and Specialty Pharma markets[32]. - The company anticipates using proceeds from the divestment to support high-growth commercial and strategic product development activities at Scienture, LLC[32]. - The company entered into a Membership Interest Purchase Agreement with Tollo Health, Inc. to sell all membership interests in IPS for $5 million, payable via a promissory note[153]. - Tollo has agreed to pay the company $5 million for acquiring IPS and Bonum, with a promissory note maturing on June 30, 2030[168]. Research and Development - Scienture, LLC is engaged in the research and development of branded pharmaceutical products, with a focus on addressing unmet medical needs[27]. - The Company identified product technology assets related to potential treatments for hypertension, migraine, pain, and thrombosis, which are in various phases of development[53]. - Management expects SCN-102 to achieve regulatory approval in mid-2025, with commercialization projected to begin in late 2025[93]. Debt and Financing - The company needs to raise additional capital or secure debt funding to support ongoing operations, which may not be available on favorable terms, raising substantial doubt about its ability to continue as a going concern[68]. - The company entered into a Securities Purchase Agreement to issue convertible debentures with a principal amount of up to $12,222,222, with the first tranche of $3,333,333 completed on November 25, 2024[94][95]. - The outstanding balance of the Arena debentures, net of unamortized debt discount, was $1,092,461 as of March 31, 2025[101]. - The company accrued $84,167 in interest expense related to the Arena debentures during the three months ended March 31, 2025[99]. - The NVK debt of $2,000,000, which accrues interest at 15.50%, is collateralized by the company's receivables and intellectual property[107]. Stock and Equity - The company issued 240,000 common shares for services and 2.8 million shares for cash pursuant to an equity line of commitment during the first quarter of 2025[19]. - The company recognized a net increase to additional paid-in capital of $2,691,467 from the issuance of 2,800,000 shares of common stock for gross proceeds of $4,597,999 under the ELOC Agreement[127]. - The company authorized the issuance of up to 9,211,246 shares of Series X Preferred Stock, replacing the revoked Series A Preferred Stock[113]. - In connection with the Scienture Merger, 291,536 shares of common stock and 6,826,753 shares of Series X Preferred Stock were issued[115]. Expenses - Operating expenses totaled $3,571,990, a decrease of 35% from $5,492,971 in the comparable period in 2024[185]. - Wage and salary expenses increased by 213% to $696,068, attributed to executive salary increases and the Scienture Merger[188]. - Professional fees rose by 130% to $412,850, mainly due to post-acquisition expenses related to Scienture[189]. - General and administrative expenses decreased by 71% to $1,355,948, primarily due to a reduction in the fair value of shares issued for services[191]. - Interest expense increased significantly to $670,784 from $98,515, driven by interest on Scienture's convertible debt[192]. Goodwill and Intangible Assets - The Company acquired intangible assets valued at $76,400,000 and recognized goodwill of $21,372,960 from the Scienture acquisition[48]. - As of March 31, 2025, no impairment of goodwill was recognized, indicating that the fair value of reporting units exceeded their carrying values[52]. - The Company did not record any impairment charge for the three months ended March 31, 2025 and 2024[56]. - Goodwill is tested annually for impairment and is not amortized, with management regularly reviewing operating results[49]. - The product technology assets will be amortized over their expected remaining life of 15-20 years once placed in service[54].

TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losa ...

TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., ...

TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. ...

Revenue and Profitability - The Company reported revenues of $136,643 for the year ended December 31, 2024, a decrease of $1,227,187 or 90% compared to $1,363,830 in 2023, primarily due to the disposition of Softell's assets and operations [463][464]. - Gross profit for 2024 was $6,005, a decrease of $43,026 or 88% from $49,031 in 2023, with a gross profit margin of 4.39% compared to 3.60% in 2023 [465]. - The net loss from continuing operations for 2024 was $18,778,876, an increase of $10,296,011 or 121% compared to $8,482,864 in 2023 [463]. - The company recognized a net loss from continuing operations of $18,244,480 for the year ended December 31, 2024, compared to a net loss of $8,482,864 for the year ended December 31, 2023 [474]. Expenses - Cost of goods sold for 2024 was $130,638, down $1,184,162 or 90% from $1,314,800 in 2023, reflecting fewer revenue-generating operations [465]. - Operating expenses increased to $14,707,020 in 2024, up $10,261,538 or 231% from $4,445,482 in 2023, driven by significant increases in general and administrative expenses [463]. - Wages and salary expense increased by $1,484,520 to $2,111,067 for the year ended December 31, 2024, compared to $626,547 for the same period in 2023 [466]. - Professional fees rose by $583,196 to $1,458,332 compared to $875,136 for the comparable period in 2023, primarily due to increased Board members' fees and consulting expenses [467]. - General and administrative expenses increased by $5,369,446 to $6,706,082 for the year ended December 31, 2024, compared to $1,336,637 for the same period in 2023, mainly due to shares issued for services valued at $4,598,294 [469]. - Research and development expenses related to Scienture LLC's operations post-acquisition totaled $2,236,690 for the year ended December 31, 2024 [471]. Cash Flow and Financial Position - Cash used in operating activities for 2024 was $14,265,238, compared to $2,225,192 in 2023, marking an increase of $12,040,046 or 541% [458][459]. - Cash provided by investing activities for 2024 was $27,552,791, a significant increase from cash used of $275,717 in 2023, primarily due to the MMS disposition and acquisition of Scienture, Inc. [460]. - The Company had an accumulated deficit of $39,038,973 and cash of $308,096 as of December 31, 2024 [456]. - Cash increased to $308,096 as of December 31, 2024, compared to $314 as of December 31, 2023, marking a 98020% increase [477]. - Current assets (excluding cash) rose by $3,244,632 to $5,997,381 for the year ended December 31, 2024, representing a 118% increase compared to $2,752,749 in 2023 [477]. Dividends and Capital Raising - The company declared a special cash dividend of $8.00 per share, totaling $12,671,072, payable on March 22, 2024 [479]. - A second special cash dividend of $1.50 per share was declared, totaling $2,187,759, payable on July 22, 2024 [480]. - The Company plans to raise additional capital through equity and debt to support ongoing operations and potential acquisitions, but there is uncertainty regarding the availability of favorable terms [457][454]. Strategic Decisions - The Company is in the process of determining a divestment and winddown plan for Softell and IPS, with the Board of Directors approving this plan on January 25, 2025 [447]. - Net income from discontinued operations increased by $36,670,988 to $27,310,278 for the year ended December 31, 2024, compared to a net loss of $9,360,710 for the year ended December 31, 2023 [475].

TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of ...

TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension, wh ...

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned ...

Core Viewpoint - Scienture Holdings, Inc. has entered into a definitive agreement with Summit Biosciences for the exclusive U.S. rights to launch REZENOPY, a naloxone HCl nasal spray, aimed at addressing the opioid overdose crisis [1][4]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on developing and distributing novel specialty pharmaceutical products to meet unmet market needs [11]. - Scienture, LLC is a specialty pharmaceutical company with a team dedicated to bringing unique products to market [11]. Product Details - REZENOPY (naloxone HCl) Nasal Spray 10mg is the most potent version of naloxone available, designed for emergency treatment of opioid overdose [3][7]. - The product is intended for intranasal use and is supplied in a carton containing two blister packages, each with a single spray device [7]. Collaboration and Manufacturing - Kindeva Drug Delivery will manufacture and supply REZENOPY, while Scienture will own the new drug application and handle sales, marketing, and distribution in the U.S. [2]. - This collaboration is seen as a strategic step to enhance public health initiatives and improve access to life-saving interventions for those at risk of opioid overdose [4][6]. Market Context - The nasal delivery of naloxone HCl is recognized for its efficacy and ease of use, making it a vital tool for first responders and healthcare providers [5]. - According to IQVIA data, the total annual sales for naloxone in the U.S. market reached $189 million, with a unit volume of 10 million [5].

Core Insights - Scienture Holdings, Inc. is participating in the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, focusing on drug discovery and development [1][3] - Dr. Narasimhan Mani will present on technology-driven product innovations and market strategies in the specialty pharmaceutical industry [2][5] - The SSX conference aims to facilitate knowledge sharing among scientists and industry experts in the field of drug discovery [3] Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing novel specialty pharmaceutical products to meet unmet market needs [5] - The company is involved in various therapeutic areas and markets, including government organizations, hospitals, and independent pharmacies [5] Conference Details - The SSX 2025 Conference will take place from January 23-25, 2025, at BITS Pilani, Hyderabad Campus [1] - The event will feature expert panels, presentations, and networking opportunities with industry veterans [7]